Cyrano Therapeutics Reports Positive Phase 2 Results for CYR-064 in Persistent Post-Viral Smell Loss
核心洞察
Cyrano Therapeutics (搜索) announced positive topline results from its Phase 2 FLAVOR trial of CYR-064, marking the first randomized controlled trial to demonstrate a pharmaceutical agent can safely improve smell function in patients with persistent post-viral hyposmia (搜索).
The randomized, double-blind, placebo-controlled study enrolled 151 patients with persistent hyposmia (搜索) lasting at least 6 months and met its primary safety endpoint with no treatment-related serious adverse events.
CYR-064 demonstrated durable improvements in smell function across multiple prespecified secondary efficacy endpoints, positioning it as a potential first-to-market therapy for over 60 million patients suffering from persistent post-viral hyposmia (搜索).
Cyrano Therapeutics (搜索) announced positive topline results from its Phase 2 FLAVOR trial of CYR-064, an intranasal soft-mist spray for treating persistent post-viral loss of smell (hyposmia (搜索)). The randomized, double-blind, placebo-controlled study represents the first clinical trial to demonstrate that a pharmaceutical agent can safely improve smell function in patients with persistent post-viral hyposmia (搜索).
Trial Design and Results
The FLAVOR trial enrolled 151 patients with persistent hyposmia (搜索) lasting at least 6 months across 14 clinical sites in the United States. The study met its primary endpoint, demonstrating the safety and tolerability of CYR-064 with no treatment-related serious adverse events reported.
Beyond safety, CYR-064 demonstrated durable improvements in smell function across multiple prespecified secondary efficacy endpoints. The company plans to present detailed trial data at an upcoming medical conference in 2026.
"This is the first randomized, controlled trial to show a pharmaceutical agent can safely improve smell function in patients with persistent post-viral hyposmia (搜索)," said Rick Geoffrion, President and CEO of Cyrano Therapeutics (搜索). "Once a person has lost their sense of smell for as long as 6 months, the chances become extremely small that their sense of smell will return."
Mechanism and Therapeutic Approach
CYR-064 is a patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (搜索) (PDE) inhibitor with a targeted delivery system designed to enhance olfactory neuron (搜索) excitability and restore the sense of smell. The regenerative therapy approach addresses the underlying neurological dysfunction associated with post-viral smell loss.
Dr. Mas Takashima, Chairman of the Department of Otolaryngology - Head and Neck Surgery at Houston Methodist Hospital and Primary Investigator for the FLAVOR trial, emphasized the clinical significance: "We now have the first randomized clinical trial data evaluating a targeted regenerative therapy for post-viral smell loss. We currently have no effective options for the tens of millions of patients in the U.S. and worldwide experiencing post-viral smell loss and its associated impact on taste."
Addressing Significant Unmet Medical Need
Post-viral hyposmia (搜索) represents a serious chronic sensory condition affecting more than 60 million people in the United States, Europe, and Japan. The condition commonly impacts both smell and taste, with patients losing up to 80% of their perception of taste when smell is impaired.
The disorder causes significant impairment in quality of life, nutritional deficits, depression, safety risks, and increased risk of cognitive decline and mortality in older adults. Currently, no approved drug therapy exists for this condition, leaving patients with limited treatment options.
Development Timeline
Based on the positive Phase 2 results, Cyrano Therapeutics (搜索) plans to advance CYR-064 into Phase 3 development in the second half of 2026. The therapy has the potential to become the first approved treatment for persistent post-viral hyposmia (搜索), addressing a substantial unmet medical need in this patient population.